Search Results - "Pruis, Melinda A."

A Phase I Trial of the Dual MET Kinase/OCT-2 Inhibitor OMO-1 in Metastatic Solid Malignancies Including MET Exon 14 Mutated Lung Cancer by Pruis, Melinda A, Krebs, Matthew G, Plummer, Ruth, De Vos, Filip, Angevin, Eric, Prenen, Hans, Forster, Martin D, Clack, Glen, Van der Aa, Annegret, Tjwa, Marc, Jansen, Ellen, Perera, Timothy, Lolkema, Martijn P

“…Targeted therapy in non-small cell lung cancer (NSCLC) patients with mesenchymal epithelial transition (MET) exon 14 skipping mutations (METex14) and MET…”
Get full text

Personalised selection of experimental treatment in patients with advanced solid cancer is feasible using whole-genome sequencing by Pruis, Melinda A., Groenendijk, Floris H., Badloe, K. Sangeeta, van Puffelen, Andrea, Robbrecht, Debbie, Dinjens, Winand N. M., Sleijfer, Stefan, Dingemans, Anne-Marie C., von der Thüsen, Jan H., Roepman, Paul, Lolkema, Martijn P.

“…Background Biomarker-guided therapy in an experimental setting has been suggested to improve patient outcomes. However, trial-specific pre-screening tests are…”
Get full text

Analysis of Serious Weight Gain in Patients Using Alectinib for ALK-Positive Lung Cancer by de Leeuw, Simon P, Pruis, Melinda A, Sikkema, Barend J, Mohseni, Mostafa, Veerman, G D Marijn, Paats, Marthe S, Dumoulin, Daphne W, Smit, Egbert F, Schols, Annemie M W J, Mathijssen, Ron H J, van Rossum, Elisabeth F C, Dingemans, Anne-Marie C

“…Alectinib is a standard-of-care treatment for metastatic ALK+ NSCLC. Weight gain is an unexplored side effect reported in approximately 10%. To prevent or…”
Get more information

A Lung Cancer Patient with Dyspnea: Diagnostic Difficulties during the COVID-19 Pandemic by Pruis, Melinda A., Hussain, Burhan, Bakker, Marleen, Hoek, Rogier A.S., Miedema, Jelle R., Dingemans, Anne-Marie C., Paats, Marthe S.

Get full text

Renal function-based versus standard dosing of pemetrexed: a randomized controlled trial by de Rouw, Nikki, Boosman, René J., Burgers, Jacobus A., Huitema, Alwin D. R., Dingemans, Anne-Marie C., Derijks, Hieronymus. J., Burger, David M., Piet, Berber, Hendriks, Lizza E. L., Biesma, Bonne, Pruis, Melinda A., Dumoulin, Daphne W., Croes, Sander, Mathijssen, Ron H. J., van den Heuvel, Michel M., ter Heine, Rob

“…Purpose Pemetrexed is a chemotherapeutic drug in the treatment of non-small cell lung cancer and mesothelioma. Optimized dosing of pemetrexed based on renal…”
Get full text

Overcoming Acquired Resistance Mutation MET D1228N to Crizotinib With Cabozantinib in NSCLC With MET Exon 14 Skipping Mutation by Pruis, Melinda A, Paats, M S, Geurts, W R R, Dubbink, H J, Dingemans, A-M C

Get more information

MET immunochemistry: a reliable screening tool for MET exon 14 skipping mutations in non-small cell lung cancer? by Pruis, Melinda A, von der Thüsen, Jan H, Dubbink, Hendrikus Jan

Get full text

Plasma Predictive Features in Treating EGFR-Mutated Non-Small Cell Lung Cancer by Steendam, Christi M J, Veerman, G D Marijn, Pruis, Melinda A, Atmodimedjo, Peggy, Paats, Marthe S, van der Leest, Cor, von der Thüsen, Jan H, Yick, David C Y, Oomen-de Hoop, Esther, Koolen, Stijn L W, Dinjens, Winand N M, van Schaik, Ron H N, Mathijssen, Ron H J, Aerts, Joachim G J V, Dubbink, Hendrikus Jan, Dingemans, Anne-Marie C

“…Although epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors (TKIs) are the preferred treatment for patients with -mutated non-small cell lung…”
Get full text

Cardiac Toxicity of Alectinib in Patients With ALK+ Lung Cancer: Outcomes of Cardio-Oncology Follow-Up by Pruis, Melinda A, Veerman, G D Marijn, Hassing, H Carlijne, Lanser, Daan A C, Paats, Marthe S, van Schaik, Ron H N, Mathijssen, Ron H J, Manintveld, Olivier, Dingemans, Anne-Marie C

“…Anaplastic lymphoma kinase (ALK) translocations in metastatic non-small cell lung cancer (3% to 7%) predict for response to ALK-inhibitors (eg, alectinib,…”
Get full text

Cardiac Toxicity of Alectinib in Patients With ALK+ Lung Cancer by Pruis, Melinda A., Veerman, G.D. Marijn, Hassing, H. Carlijne, Lanser, Daan A.C., Paats, Marthe S., van Schaik, Ron H.N., Mathijssen, Ron H.J., Manintveld, Olivier, Dingemans, Anne-Marie C.

“…Anaplastic lymphoma kinase (ALK) translocations in metastatic non-small cell lung cancer (3% to 7%) predict for response to ALK-inhibitors (eg, alectinib,…”
Get full text